Time resolved gene expression analysis during tamoxifen adaption of MCF-7 cells identifies long non-coding RNAs with prognostic impact.
Breast Neoplasms
/ drug therapy
Cell Movement
Cell Proliferation
Drug Resistance, Neoplasm
Female
Gene Expression Profiling
/ methods
Gene Expression Regulation, Neoplastic
Gene Regulatory Networks
Humans
MCF-7 Cells
Prognosis
RNA, Long Noncoding
/ genetics
Receptors, Estrogen
/ metabolism
Tamoxifen
Time Factors
Breast cancer
biomarker
gene expression
long-non coding RNAs
tamoxifen
Journal
RNA biology
ISSN: 1555-8584
Titre abrégé: RNA Biol
Pays: United States
ID NLM: 101235328
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
pmc-release:
05
03
2020
pubmed:
15
2
2019
medline:
27
11
2019
entrez:
15
2
2019
Statut:
ppublish
Résumé
Acquired tamoxifen resistance is a persistent problem for the treatment of estrogen receptor positive, premenopausal breast cancer patients and predictive biomarkers are still elusive. We here analyzed gene expression changes in a cellular model to identify early and late changes upon tamoxifen exposure and thereby novel prognostic biomarkers. Estrogen receptor positive MCF-7 cells were incubated with 4OH-tamoxifen (10 nM) and gene expression analyzed by array hybridization during 12 weeks. Array results were confirmed by nCounter- and qRT-PCR technique. Pathway enrichment analysis revealed that early responses concerned mainly amine synthesis and NRF2-related signaling and evolved into a stable gene expression pattern within 4 weeks characterized by changes in glucuronidation-, estrogen metabolism-, nuclear receptor- and interferon signaling pathways. As a large number of long non coding RNAs was subject to regulation, we investigated 5 of these (linc01213, linc00632 linc0992, LOC101929547 and XR_133213) in more detail. From these, only linc01213 was upregulated but all were less abundant in estrogen-receptor negative cell lines (MDA-MB 231, SKBR-3 and UACC3199). In a web-based survival analysis linc01213 and linc00632 turned out to have prognostic impact. Linc01213 was investigated further by plasmid-mediated over-expression as well as siRNA down-regulation in MCF-7 cells. Nevertheless, this had no effect on proliferation or expression of tamoxifen regulated genes, but migration was increased. In conclusion, the cellular model identified a set of lincRNAs with prognostic relevance for breast cancer. One of these, linc01213 although regulated by 4OH-tamoxifen, is not a central regulator of tamoxifen adaption, but interferes with the regulation of migration.
Identifiants
pubmed: 30760083
doi: 10.1080/15476286.2019.1581597
pmc: PMC6546408
doi:
Substances chimiques
RNA, Long Noncoding
0
Receptors, Estrogen
0
Tamoxifen
094ZI81Y45
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
661-674Références
Nature. 2000 Mar 23;404(6776):411-4
pubmed: 10746731
Clin Cancer Res. 2004 Apr 1;10(7):2336-43
pubmed: 15073109
Endocr Relat Cancer. 2004 Dec;11(4):643-58
pubmed: 15613444
Mol Cancer Ther. 2005 Jan;4(1):151-68
pubmed: 15657362
Nat Chem Biol. 2006 Apr;2(4):207-12
pubmed: 16520733
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9063-8
pubmed: 16754886
Mol Cell Endocrinol. 2008 Dec 16;296(1-2):1-9
pubmed: 18951949
Oncology (Williston Park). 2008 Oct;22(11):1233-9; discussion 1239-40, 1243
pubmed: 18980022
Nucleic Acids Res. 2009 Jan;37(1):1-13
pubmed: 19033363
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Steroids. 2009 Jul;74(7):586-94
pubmed: 19138696
Nat Chem Biol. 2009 Jun;5(6):421-7
pubmed: 19430488
J Clin Oncol. 2009 Jul 20;27(21):3423-9
pubmed: 19487384
Lancet Oncol. 2009 Aug;10(8):825-33
pubmed: 19647203
Breast Cancer Res Treat. 2010 Aug;123(1):87-96
pubmed: 19911269
Breast Cancer Res Treat. 2010 Oct;123(3):725-31
pubmed: 20020197
Breast Cancer Res. 2009;11(6):112
pubmed: 20067604
Mol Endocrinol. 2010 Apr;24(4):709-21
pubmed: 20197310
Bioinformatics. 2010 Oct 1;26(19):2438-44
pubmed: 20709693
Breast Cancer Res Treat. 2011 Jul;128(2):457-66
pubmed: 21607586
Lancet. 2011 Aug 27;378(9793):747-9
pubmed: 21802719
Mol Cell. 2011 Sep 16;43(6):904-14
pubmed: 21925379
Oncogene. 2013 Feb 28;32(9):1173-82
pubmed: 22508479
Bioinformatics. 2012 Jun 1;28(11):1546-8
pubmed: 22513995
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
PLoS One. 2012;7(7):e41333
pubmed: 22844461
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Mol Oncol. 2013 Jun;7(3):611-24
pubmed: 23499324
Int J Oncol. 2013 May;42(5):1770-7
pubmed: 23525470
Eur J Pharmacol. 2013 Oct 5;717(1-3):47-57
pubmed: 23545365
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
Breast Cancer Res Treat. 2013 May;139(1):71-80
pubmed: 23609470
Breast Cancer Res. 2013 Nov 29;15(6):R114
pubmed: 24289103
Sci Rep. 2014 Feb 17;4:4057
pubmed: 24531845
Science. 2014 Mar 28;343(6178):1452-3
pubmed: 24675948
Breast Cancer Res Treat. 2014 May;145(1):61-71
pubmed: 24715381
J Pathol. 2014 Aug;233(4):368-79
pubmed: 24752803
Front Endocrinol (Lausanne). 2014 May 06;5:66
pubmed: 24834064
Oncogene. 2015 Apr 9;34(15):1919-27
pubmed: 24882577
PLoS One. 2014 Jul 01;9(7):e101473
pubmed: 24983248
Breast Cancer Res Treat. 2014 Sep;147(2):423-31
pubmed: 25007959
Eur J Cancer. 2014 Nov;50(16):2866-76
pubmed: 25204804
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Pathol Res Pract. 2015 Mar;211(3):189-97
pubmed: 25666016
PLoS Comput Biol. 2015 Feb 23;11(2):e1004085
pubmed: 25706687
Am J Transl Res. 2015 Jan 15;7(1):120-7
pubmed: 25755834
J Mol Neurosci. 2015 Oct;57(2):197-202
pubmed: 26109525
Mol Cancer Ther. 2015 Nov;14(11):2411-21
pubmed: 26333382
Steroids. 2016 Jul;111:95-99
pubmed: 26884313
Biochim Biophys Acta. 2016 Jun;1860(6):1272-80
pubmed: 26971627
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Sci Rep. 2016 Jun 24;6:27931
pubmed: 27338266
Oncotarget. 2016 Aug 30;7(35):57239-57253
pubmed: 27528030
Cell Biol Toxicol. 2016 Dec;32(6):563-581
pubmed: 27585693
Nat Commun. 2016 Sep 26;7:12791
pubmed: 27666543
Pathology. 2017 Feb;49(2):111-119
pubmed: 28040199
Oncotarget. 2017 Mar 7;8(10):16642-16649
pubmed: 28186965
Nucleic Acids Res. 2017 Jul 3;45(W1):W130-W137
pubmed: 28472511
Mol Cancer. 2017 Oct 17;16(1):161
pubmed: 29041978
Endocr Relat Cancer. 2018 Apr;25(4):R259-R282
pubmed: 29440232
Sci Rep. 2018 Feb 16;8(1):3179
pubmed: 29453409
Oncologist. 2018 Aug;23(8):974-981
pubmed: 29934412
Breast Cancer. 2019 Mar;26(2):249-254
pubmed: 30066060
Noncoding RNA. 2018 Dec 12;4(4):null
pubmed: 30545127
Cancer Res. 1985 Apr;45(4):1525-31
pubmed: 3978620
Cancer Res. 1984 Nov;44(11):5038-45
pubmed: 6488162
Science. 1997 Jan 17;275(5298):343-9
pubmed: 8994024